This review summarizes recent progress in IL-15-based cancer immunotherapy, integrates emerging insights into IL-2R<i>βγ</i>-driven CD8<sup>+</sup> T-cell fate decisions, and discusses key opportunities and challenges for translating IL-15-mediated immune enhancement into durable clinical benefit. Here, IL2RA is linked to cancer.